Resultados de la búsqueda 281-290 of 11255 for anti-TNF drugs

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung ...

2. Hematología - Ensayos clínicos - Mayo Clinic

   This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.

3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, ...

4. Hematología - Ensayos clínicos - Mayo Clinic

   This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.

5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Chemotherapy drugs, such as capecitabine and ... anti-cancer treatment and have a positive 68Ga ... The purpose of this study is to learn if the study drug, [225Ac] ...

6. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

   Testing The Addition Of An Anti-cancer Drug, ASTX727, To Chemotherapy ... The names of the study drugs involved in this study are: * Axatilimab (a type ...

7. Hematología - Ensayos clínicos - Mayo Clinic

   Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung ...

8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   In addition, obesity, a chronic inflammatory state, is associated with increased colorectal cancer risk (5). However, the use of anti-inflammatory agents in the ...

9. Hematología - Ensayos clínicos - Mayo Clinic

   Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung ...

10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Anti-cancer activity will be assessed every 6 weeks during therapy and every 12 weeks thereafter. Prospective Use Of Philips ISuite For Interventional ...